CABA (Cabaletta Bio, Inc. Common Stock)
Insider Trading Activity
Every open-market purchase and sale reported by CABA officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-06-10 | Shawn Tomasello | Director | A | — | — |
| 2026-06-10 | Catherine Bollard | Director | A | — | — |
| 2026-06-10 | Mark Simon | Director | A | — | — |
| 2026-06-10 | RICHARD C HENRIQUES JR | Director | A | — | — |
| 2026-06-10 | Scott C. Brun | Director | A | — | — |
| 2026-03-02 | Michael Gerard | General Counsel | A | — | — |
| 2026-03-02 | Arun Das | Chief Business Officer | A | — | — |
| 2026-03-02 | Steven Nichtberger | President & CEO | A | — | — |
| 2026-03-02 | Anup Marda | Chief Financial Officer | A | — | — |
| 2026-03-02 | David J. Chang | Chief Medical Officer | A | — | — |
| 2026-03-02 | Gwendolyn Binder | President, Science & Tech. | A | — | — |
| 2026-01-21 | Steve Gavel | Chief Commercial Officer | Buy | — | — |
| 2026-01-21 | Shawn Tomasello | Director | Buy | — | — |
| 2026-01-21 | Catherine Bollard | Director | Buy | — | — |
| 2026-01-21 | Michael Gerard | General Counsel | Buy | — | — |
| 2026-01-21 | Mark Simon | Director | Buy | — | — |
| 2026-01-21 | Gwendolyn Binder | President, Science & Tech. | Buy | — | — |
| 2026-01-21 | David J. Chang | Chief Medical Officer | Buy | — | — |
| 2026-01-21 | Steven Nichtberger | President & CEO | Buy | — | — |
| 2025-10-15 | Steve Gavel | CHIEF COMMERCIAL OFFICER | A | — | — |
| 2025-06-09 | Scott C. Brun | Director | A | — | — |
| 2025-06-09 | Catherine Bollard | Director | A | — | — |
| 2025-06-09 | RICHARD C HENRIQUES JR | Director | A | — | — |
| 2025-06-09 | Shawn Tomasello | Director | A | — | — |
| 2025-06-09 | Mark Simon | Director | A | — | — |
| 2025-05-19 | RICHARD C HENRIQUES JR | Director | MIXED | — | — |
| 2025-05-19 | Catherine Bollard | Director | MIXED | — | — |
| 2025-05-19 | Scott C. Brun | Director | MIXED | — | — |
| 2025-05-19 | Shawn Tomasello | Director | MIXED | — | — |
| 2025-05-19 | Gwendolyn Binder | President, Science & Tech. | MIXED | — | — |
| 2025-05-19 | Arun Das | Chief Business Officer | MIXED | — | — |
| 2025-05-19 | Anup Marda | Chief Financial Officer | MIXED | — | — |
| 2025-05-19 | Michael Gerard | General Counsel | MIXED | — | — |
| 2025-05-19 | Steven Nichtberger | President & CEO | MIXED | — | — |
| 2025-05-19 | Mark Simon | Director | MIXED | — | — |
| 2025-05-19 | David J. Chang | Chief Medical Officer | MIXED | — | — |
| 2025-03-04 | Anup Marda | Chief Financial Officer | A | — | — |
| 2025-03-04 | Gwendolyn Binder | President, Science & Tech. | A | — | — |
| 2025-03-04 | Steven Nichtberger | President & CEO | A | — | — |
| 2025-03-04 | Arun Das | Chief Business Officer | A | — | — |
| 2025-03-04 | David J. Chang | Chief Medical Officer | A | — | — |
| 2025-03-04 | Michael Gerard | General Counsel | A | — | — |
| 2024-06-04 | Shawn Tomasello | Director | A | — | — |
| 2024-06-04 | Scott C. Brun | Director | A | — | — |
| 2024-06-04 | RICHARD C HENRIQUES JR | Director | A | — | — |
| 2024-06-04 | Mark Simon | Director | A | — | — |
| 2024-06-04 | Catherine Bollard | Director | A | — | — |
| 2024-03-04 | Steven Nichtberger | President & CEO | A | — | — |
| 2024-03-04 | Anup Marda | Chief Financial Officer | A | — | — |
| 2024-03-04 | David J. Chang | Chief Medical Officer | A | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | 10%+ Owner | 3,214,721 | — |
| — | 10%+ Owner | 2,953,634 | — |
| — | 10%+ Owner | 1,731,119 | — |
| — | President & CEO | 1,394,483 | — |
| — | 10%+ Owner | 700,000 | — |
| — | 10%+ Owner | 696,378 | — |
| — | 10%+ Owner | 380,218 | — |
| — | 10%+ Owner | 369,688 | — |
| — | Director | 154,205 | — |
| — | Chief Financial Officer | 50,000 | — |
| — | President, Science & Tech. | 31,312 | — |
| — | Director | 22,725 | — |
| — | Chief Commercial Officer | 22,170 | — |
| — | Chief Medical Officer | 8,800 | — |
| — | General Counsel | 6,600 | — |
| — | Director | 5,405 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the CABA quote page; the site-wide leaderboard is on the insider transactions hub.